A Study to Determine How Corneal Transparency is Affected in Fuchs Dystrophy

Overview

About this study

The purpose of this study is to determine how corneal transparency is affected in Fuchs dystrophy, and if a measure of corneal transparency (haze) can help grade the severity of the disease.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Fuchs group

Presence of central or paracentral corneal guttae
Any age (expected range will be 40-90)
Any sex or race

Normal group

Absence of central or paracentral corneal guttae
Ages 51-80 (to match the predominant age of subjects with Fuchs dystrophy)
Any sex or race

Exclusion Criteria:

Any corneal disease (except Fuchs dystrophy in the Fuchs group)
Previous ocular surgery (except for cataract surgery with posterior chamber intraocular lens in the Fuchs dystrophy group)
Use of topical ocular medications, expect artificial tears
Glaucoma or ocular hypertension
Systemic diseases known to affect the cornea, e.g. diabetes

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Sanjay Patel, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Sanjay Patel, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials